Nielsen DL, Palshof JA, Larsen FO, Jensen BV, Pfeiffer P. A systematic review of salvage therapy to patients with metastatic colorectal cancer previously treated with fluorouracil, oxaliplatin and irinotecan +/− targeted therapy. Cancer Treat Rev. 2014;40:701–15.

Article  CAS  PubMed  Google Scholar 

Fodde R, Smits R, Clevers H. APC, signal transduction and genetic instability in colorectal cancer. Nat Rev Cancer. 2001;1:55–67.

Article  CAS  PubMed  Google Scholar 

Nishisho I, Nakamura Y, Miyoshi Y, Miki Y, Ando H, Horii A, et al. Mutations of chromosome 5q21 genes in FAP and colorectal cancer patients. Science 1991;253:665–9.

Article  CAS  PubMed  Google Scholar 

Daniloski Z, Bisht KK, McStay B, Smith S. Resolution of human ribosomal DNA occurs in anaphase, dependent on tankyrase 1, condensin II, and topoisomerase IIalpha. Genes Dev. 2019;33:276–81.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ohishi T, Yoshida H, Katori M, Migita T, Muramatsu Y, Miyake M, et al. Tankyrase-binding protein TNKS1BP1 regulates actin cytoskeleton rearrangement and cancer cell invasion. Cancer Res. 2017;77:2328–38.

Article  CAS  PubMed  Google Scholar 

Smith S, Giriat I, Schmitt A, de Lange T. Tankyrase, a poly(ADP-ribose) polymerase at human telomeres. Science 1998;282:1484–7.

Article  CAS  PubMed  Google Scholar 

Callow MG, Tran H, Phu L, Lau T, Lee J, Sandoval WN, et al. Ubiquitin ligase RNF146 regulates tankyrase and Axin to promote Wnt signaling. PLoS One. 2011;6:e22595.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Huang SM, Mishina YM, Liu S, Cheung A, Stegmeier F, Michaud GA, et al. Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. Nature 2009;461:614–20.

Article  CAS  PubMed  Google Scholar 

Zhang Y, Liu S, Mickanin C, Feng Y, Charlat O, Michaud GA, et al. RNF146 is a poly(ADP-ribose)-directed E3 ligase that regulates axin degradation and Wnt signalling. Nat Cell Biol. 2011;13:623–9.

Article  CAS  PubMed  Google Scholar 

Riffell JL, Lord CJ, Ashworth A. Tankyrase-targeted therapeutics: expanding opportunities in the PARP family. Nat Rev Drug Discov. 2012;11:923–36.

Article  CAS  PubMed  Google Scholar 

Seimiya H. Crossroads of telomere biology and anticancer drug discovery. Cancer Sci. 2020;111:3089–99.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen B, Dodge ME, Tang W, Lu J, Ma Z, Fan CW, et al. Small molecule-mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer. Nat Chem Biol. 2009;5:100–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lau T, Chan E, Callow M, Waaler J, Boggs J, Blake RA, et al. A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth. Cancer Res. 2013;73:3132–44.

Article  CAS  PubMed  Google Scholar 

Quackenbush KS, Bagby S, Tai WM, Messersmith WA, Schreiber A, Greene J, et al. The novel tankyrase inhibitor (AZ1366) enhances irinotecan activity in tumors that exhibit elevated tankyrase and irinotecan resistance. Oncotarget 2016;7:28273–85.

Article  PubMed  PubMed Central  Google Scholar 

Mizutani A, Yashiroda Y, Muramatsu Y, Yoshida H, Chikada T, Tsumura T, et al. RK-287107, a potent and specific tankyrase inhibitor, blocks colorectal cancer cell growth in a preclinical model. Cancer Sci. 2018;109:4003–14.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shirai F, Mizutani A, Yashiroda Y, Tsumura T, Kano Y, Muramatsu Y, et al. Design and discovery of an orally efficacious spiroindolinone-based tankyrase inhibitor for the treatment of colon cancer. J Med Chem. 2020;63:4183–204.

Article  CAS  PubMed  Google Scholar 

Shirai F, Tsumura T, Yashiroda Y, Yuki H, Niwa H, Sato S, et al. Discovery of novel spiroindoline derivatives as selective tankyrase inhibitors. J Med Chem. 2019;62:3407–27.

Article  CAS  PubMed  Google Scholar 

Zhong Y, Katavolos P, Nguyen T, Lau T, Boggs J, Sambrone A, et al. Tankyrase inhibition causes reversible intestinal toxicity in mice with a therapeutic index <1. Toxicol Pathol. 2016;44:267–78.

Article  CAS  PubMed  Google Scholar 

Kim DY, Kwon YJ, Seo WY, Kim UI, Ahn S, Choi SM, et al. Tankyrase-selective inhibitor STP1002 shows preclinical antitumour efficacy without on-target toxicity in the gastrointestinal tract. Eur J Cancer. 2022;173:41–51.

Article  CAS  PubMed  Google Scholar 

Brinch SA, Amundsen-Isaksen E, Espada S, Hammarstrom C, Aizenshtadt A, Olsen PA, et al. The tankyrase inhibitor OM-153 demonstrates antitumor efficacy and a therapeutic window in mouse models. Cancer Res Commun. 2022;2:233–45.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tanaka N, Mashima T, Mizutani A, Sato A, Aoyama A, Gong B, et al. APC mutations as a potential biomarker for sensitivity to tankyrase inhibitors in colorectal cancer. Mol Cancer Ther. 2017;16:752–62.

Article  CAS  PubMed  Google Scholar 

Jang MK, Mashima T, Seimiya H. Tankyrase inhibitors target colorectal cancer stem cells via AXIN-dependent downregulation of c-KIT tyrosine kinase. Mol Cancer Ther. 2020;19:765–76.

Article  CAS  PubMed  Google Scholar 

Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics 2014;30:2114–20.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li H. Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM. arXiv 2013;1303:3997v2.

Google Scholar 

Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, et al. The sequence alignment/map format and SAMtools. Bioinformatics 2009;25:2078–9.

Article  PubMed  PubMed Central  Google Scholar 

Cibulskis K, Lawrence MS, Carter SL, Sivachenko A, Jaffe D, Sougnez C, et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol. 2013;31:213–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, et al. The genome analysis toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 2010;20:1297–303.

Article  CAS  PubMed  PubMed Central  Google Scholar 

DePristo MA, Banks E, Poplin R, Garimella KV, Maguire JR, Hartl C, et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat Genet. 2011;43:491–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Van der Auwera GA, Carneiro MO, Hartl C, Poplin R, Del Angel G, Levy-Moonshine A, et al. From FastQ data to high confidence variant calls: the Genome Analysis Toolkit best practices pipeline. Curr Protoc Bioinforma. 2013;43:11.10.1-11.10.33.

Google Scholar 

McLaren W, Gil L, Hunt SE, Riat HS, Ritchie GR, Thormann A, et al. The Ensembl Variant Effect Predictor. Genome Biol. 2016;17:122.

Article  PubMed  PubMed Central  Google Scholar 

Mashima T, Taneda Y, Jang MK, Mizutani A, Muramatsu Y, Yoshida H, et al. mTOR signaling mediates resistance to tankyrase inhibitors in Wnt-driven colorectal cancer. Oncotarget 2017;8:47902–15.

Article  PubMed  PubMed Central  Google Scholar 

Novak A, Dedhar S. Signaling through beta-catenin and Lef/Tcf. Cell Mol Life Sci. 1999;56:523–37.

Article  CAS  PubMed  Google Scholar 

Deng X, Hamamoto R, Vougiouklakis T, Wang R, Yoshioka Y, Suzuki T, et al. Critical roles of SMYD2-mediated beta-catenin methylation for nuclear translocation and activation of Wnt signaling. Oncotarget 2017;8:55837–47.

Article  PubMed  PubMed Central  Google Scholar 

Schoumacher M, Hurov KE, Lehar J, Yan-Neale Y, Mishina Y, Sonkin D, et al. Inhibiting Tankyrases sensitizes KRAS-mutant cancer cells to MEK inhibitors via FGFR2 feedback signaling. Cancer Res. 2014;74:3294–305.

Article  CAS  PubMed  Google Scholar 

Mygland L, Brinch SA, Strand MF, Olsen PA, Aizenshtadt A, Lund K, et al. Identification of response signatures for tankyrase inhibitor treatment in tumor cell lines. iScience 2021;24:102807.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang Y, Xu X, Maglic D, Dill MT, Mojumdar K, Ng PK, et al. Comprehensive molecular characterization of the Hippo signaling pathway in cancer. Cell Rep. 2018;25:1304–17.e5.

Article